THERADIAG Strengthens Its International Presence by Signing Three New Strategic Distributors in Asia

Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, announces today that it has strengthened its international presence by signing three new strategic distributors in China, in Hong Kong-Macao and in Taiwan, to distribute its main TRACKER range biotherapy monitoring tests.

Theradiag continues to step up its international expansion into key regions showing growth potential in its business sectors.

From January 2020, Theradiag will be distributed in Hong Kong-Macao, Taiwan and also in mainland China, on a non-exclusive basis, in order to be able to seize other potential opportunities arising in this high-potential country. In China more than 5 million people suffer from rheumatoid arthritis and the incidence of chronic inflammatory diseases is increasing rapidly as well as the market of biotherapies treatments.

- In China, the partnership with Hongquan Medical Technology will give Theradiag access to an unrivaled scientific expertise in chronic inflammatory diseases in the country. Theradiag will benefit from Hongquan Medical Technology’s expertise in its two main fields of scientific research and distribution: gastroenterology and inflammatory bowel disease (IBD).

- In Hong Kong and Macao, Theradiag will partner with one of the largest and fastest growing pharmaceutical companies in the region, Hindwing, to market its products and gain access to leading hospitals in China and Asia.

- In Taiwan, Theradiag will work with Medtri, a leading medical technology company.

These three new partnerships are the sign of a conscious proactive strategy to exploit and promote Theradiag’s innovative TRACKER range.

In addition to distributing the kits, the partners will share the most recent scientific advances in biotherapy monitoring with ‘Key Opinion Leaders’ in the region. This comes in support of Asian authorities’ recommendations released in May 2019, in favor of using biotherapy monitoring tools.

Bertrand de Castelnau, Chief Executive Officer of Theradiag, commented: “We are delighted to sign these new distribution partnerships. They are fully in line with our international development strategy geared towards high-potential strategic regions such as Asia. The spontaneous interest shown by these three new partners further enhances the merits of our theranostics approach and the efficiency of our TRACKER kits in monitoring biotherapy treatment. Theradiag’s priority remains more than ever to administer the right treatment to the right patient, thanks to innovative testing that improves treatment effectiveness. All of our people are now committed to ensuring the successful implementation of these partnerships in 2020.”